osimertinib

Doctors, Payors, Lab Directors, Patients Have Distinct Views on What's Holding Up Precision Oncology

Drugmakers Push to Improve Treatment in Key NSCLC Subgroups, Find Options Where There Are Few

AstraZeneca Q1 Oncology Product Sales Increase 14 Percent Led by Tagrisso

Hutchmed Receives $15M Milestone Payment From AstraZeneca in Orpathys Codevelopment Deal

RedCloud Bio to Begin Trial of Fourth-Generation EGFR Inhibitor in NSCLC Subgroup

AstraZeneca Q4 Oncology Revenues Grow 20 percent

In Brief This Week: AstraZeneca, Daiichi Sankyo, Orgenesis, Amgen

NICE Backs AstraZeneca's Tagrisso for Adjuvant EGFR-Mutated NSCLC Through Cancer Drugs Fund

Hutchmed, AstraZeneca Begin Phase III Trial in NSCLC With EGFR, MET Mutations

AstraZeneca's Q3 Oncology Revenues Grow 18 Percent

In Brief This Week: AstraZeneca, CytoDyn, BerGenBio, Bayer, Dana-Farber Cancer Institute, Kronos Bio

ESMO Data Shed Light on Activity of Janssen's Rybrevant-Leclaza Combo in EGFR-Mutated NSCLC

Erasca Begins HERKULES-2 Trial of ERAS-007, Tagrisso in EGFR-mutated NSCLC

AstraZeneca, Hutchmed Launch Phase III Randomized Trial of Orpathys, Tagrisso in China

AstraZeneca Q2 Revenues Increase 31 Percent

Genecast to Evaluate Liquid Biopsy EGFR Mutation Test in Early-Stage Non-Small Cell Lung Cancer

UK's MHRA Grants Early Access to AstraZeneca's Tagrisso as Adjuvant NSCLC Treatment